Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies

Clinical trial NCT03151057 · TERMINATED

Trial details

NCT number: NCT03151057
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

B Cells-Tumors B Cell Chronic Lymphocytic Leukemia Follicular Lymphoma Mantle Cell Lymphoma Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)

Start date: 2018-07-31
Primary completion: 2022-06-20
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.